Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced on August 19, 2026, that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ecopipam (EBS-101). The agency granted the application Priority Review, establishing a targeted Prescription Drug User Fee Act (PDUFA) action date for late in the first quarter of 2027. Ecopipam is a first-in-class selective D1 dopamine receptor antagonist designed to treat pediatric patients with Tourette syndrome.

This regulatory milestone supports Teva’s Pivot to Growth strategy by leveraging its neuroscience expertise. Tourette syndrome affects approximately 100,000 children and adolescents in the US. Current treatment options show limited adherence, with only 20-30 percent of patients remaining on therapy after one year. Many patients experience inadequate symptom control or treatment-limiting side effects from existing medications. Only half of these patients are treated with prescription medication for this condition.

Clinical Data Supporting NDA

The NDA acceptance is underpinned by positive data from Phase 2b and Phase 3 clinical trials. In the Phase 2b study, ecopipam demonstrated statistically significant improvement in tic severity compared to placebo at Week 12 (p = 0.01), measured by the Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS). Durability of efficacy was further confirmed in a Phase 2b open-label extension study.

The Phase 3 randomized withdrawal trial, published in JAMA Neurology, evaluated maintenance of efficacy. Pediatric responders treated with ecopipam showed a 53% decreased risk of relapse over 12 weeks compared to placebo (p=0.008). The trial enrolled 216 participants, randomizing 104 individuals (90 pediatric, 14 adult) across 77 sites in North America and Europe. While adults were included in the Phase 3 trial, the accepted NDA seeks an indication exclusively for pediatric patients.

Safety Profile and Tolerability

Across Phase 2b, Phase 2b open-label extension, and Phase 3 trials, ecopipam showed no clinically meaningful changes in several key safety parameters:

• Body weight and Body Mass Index (BMI) Z-Score
• Vitals and laboratory measures, including metabolic parameters
• Electrocardiogram (ECG) measurements
• Drug-induced movement disorders (DIMD), measured by Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BARS), or Extrapyramidal Symptom Rating Scale (ESRS)
• Measures of psychiatric comorbidities

Ecopipam was generally well-tolerated. The most common adverse events reported in pediatric patients included headache, insomnia, fatigue, somnolence, tics, anxiety, nausea, and restlessness.

What the Numbers Show

The clinical data highlights a divergence between efficacy maintenance and safety profile compared to historical treatments. While existing therapies often face discontinuation due to side effects affecting weight or movement, ecopipam demonstrated no clinically meaningful changes in BMI, ECG, or drug-induced movement disorders across multiple trial phases. This suggests a potential shift in the risk-benefit ratio for pediatric patients, addressing the high discontinuation rates cited in current treatment landscapes where only half of affected children receive prescription medication.

Regulatory Context

Ecopipam holds Orphan Drug designation, reserved for patient populations of 200,000 or fewer. If approved, it would represent the first new therapy for Tourette syndrome in more than 10 years and the first novel mechanism of action in over 50 years. Previous approvals include haloperidol (1969), pimozide (1984), and aripiprazole (2014).

Teva Pharmaceutical Industries has raised its fiscal year 2026 sales guidance while maintaining its adjusted earnings per share (EPS) outlook, driven by robust performance in its innovative drug portfolio. The New York-listed pharmaceutical giant reported second-quarter adjusted earnings of $0.02 per share, missing the consensus estimate of $0.25, but delivered sales of $4.142 billion, beating the Wall Street consensus of $4.047 billion. This top-line strength was primarily fueled by a 43% year-over-year local currency growth in key innovative brands Austedo, Ajovy, and Uzedy, which collectively generated over $1 billion in revenues during the quarter.

The divergence between revenue strength and earnings miss highlights ongoing margin pressures, particularly within the generics segment. While sales decreased 1% overall (3% in local currency), the decline was attributed to lower revenues from generic products, specifically lenalidomide capsules in the U.S. Conversely, the biosimilars portfolio performed strongly and is on track to deliver $800 million in revenues by 2027. Management indicated that the company remains on track to meet its 2027 financial growth targets, expecting continued margin expansion driven by its innovative portfolio despite challenges in the generics sector.

Guidance Revisions

Teva maintained its FY26 adjusted EPS guidance at $1.91-$2.11, which includes $0.66 per share of Emalex expenses. However, the company marginally raised its FY26 sales guidance from $16.40 billion-$16.80 billion to $16.50 billion-$16.85 billion, surpassing the analyst consensus of $16.618 billion. Additionally, Teva raised its FY26 revenue outlook for its key innovative brands to approximately $3.7 billion, reflecting around 17% year-over-year growth at the midpoint.

NYSE Listing Transition

In a significant corporate development, Teva announced the replacement of its American Depositary Share (ADS) program with the direct listing of its ordinary shares on the New York Stock Exchange (NYSE). ADSs will be exchanged on a one-for-one basis for ordinary shares, which commence trading on the NYSE on Monday, Sept. 14. The transition aims to broaden Teva’s shareholder base, support its potential inclusion in leading indices, and optimize cost-of-capital. Following the earnings report, Teva shares were up 9.25% at $34.60.

What the Numbers Show

The most critical analytical takeaway is the accelerating shift in Teva’s revenue mix toward higher-margin innovative therapies. While the generics segment continues to face headwinds from competition and specific product declines like lenalidomide, the innovative brands Austedo, Ajovy, and Uzedy are growing at a rapid pace (43% YoY). This suggests that Teva’s strategic pivot away from reliance on low-margin generics is yielding tangible results. The maintenance of EPS guidance despite the Q2 miss indicates that management expects these innovative brand gains to offset generic weaknesses in the latter half of the year, supported by a robust pipeline including potential launches of olanzapine and ecopipam.